On Friday Sonnet BioTherapeutics (NASDAQ: SONN) moved 3.14% up to $2.63 on 2,303,276 shares. Slow growth indicates that long term investors are also buying SONN shares via looking at fiscal year financial results.
The last days of July were in favor of SONN that soared to $4.12 on millions of shares. Preclinical results for the development of advanced medicines to fight cancer and other oncological diseases.
Monday may be a day of slow gain too unless Sonnet unveils upcoming preclinical results again. Despite having a cash-burning situation SONN is still attractive stock to many traders. At least by 2%, SONN might grow on several thousand shares.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life